Abbott Laboratories ROE 2006-2019 | ABT
Current and historical return on equity (ROE) values for Abbott Laboratories (ABT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Abbott Laboratories ROE for the three months ending September 30, 2019 was 17.65%.
| Abbott Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2019-09-30 | $3.29B | $32.02B | 10.47% |
| 2019-06-30 | $2.90B | $31.89B | 9.29% |
| 2019-03-31 | $2.62B | $31.13B | 8.49% |
| 2018-12-31 | $2.37B | $30.72B | 7.64% |
| 2018-09-30 | $0.89B | $30.90B | 2.85% |
| 2018-06-30 | $0.93B | $30.77B | 2.95% |
| 2018-03-31 | $0.48B | $31.60B | 1.50% |
| 2017-12-31 | $0.48B | $31.10B | 1.51% |
| 2017-09-30 | $2.10B | $32.22B | 7.23% |
| 2017-06-30 | $1.17B | $31.79B | 4.46% |
| 2017-03-31 | $1.50B | $31.55B | 6.40% |
| 2016-12-31 | $1.40B | $20.72B | 6.73% |
| 2016-09-30 | $1.37B | $20.90B | 6.53% |
| 2016-06-30 | $2.28B | $20.80B | 10.82% |
| 2016-03-31 | $2.45B | $20.84B | 11.31% |
| 2015-12-31 | $4.42B | $21.33B | 20.18% |
| 2015-09-30 | $4.56B | $21.22B | 20.74% |
| 2015-06-30 | $4.52B | $23.13B | 20.14% |
| 2015-03-31 | $4.20B | $21.99B | 18.60% |
| 2014-12-31 | $2.28B | $21.64B | 9.95% |
| 2014-09-30 | $1.97B | $22.99B | 8.25% |
| 2014-06-30 | $2.40B | $23.70B | 9.96% |
| 2014-03-31 | $2.41B | $23.49B | 10.14% |
| 2013-12-31 | $2.58B | $25.27B | 10.94% |
| 2013-09-30 | $3.04B | $23.79B | 12.70% |
| 2013-06-30 | $4.02B | $22.43B | 16.22% |
| 2013-03-31 | $5.27B | $22.68B | 20.82% |
| 2012-12-31 | $5.96B | $26.81B | 22.93% |
| 2012-09-30 | $6.53B | $27.10B | 25.67% |
| 2012-06-30 | $4.89B | $24.57B | 19.69% |
| 2012-03-31 | $5.11B | $25.54B | 20.18% |
| 2011-12-31 | $4.73B | $24.53B | 18.84% |
| 2011-09-30 | $4.55B | $24.69B | 18.45% |
| 2011-06-30 | $5.14B | $26.47B | 21.54% |
| 2011-03-31 | $4.49B | $24.72B | 20.18% |
| 2010-12-31 | $4.63B | $22.77B | 21.71% |
| 2010-09-30 | $4.73B | $21.48B | 22.06% |
| 2010-06-30 | $5.31B | $20.00B | 24.84% |
| 2010-03-31 | $5.31B | $21.01B | 24.84% |
| 2009-12-31 | $5.75B | $23.19B | 27.87% |
| 2009-09-30 | $5.74B | $21.38B | 29.91% |
| 2009-06-30 | $5.35B | $19.92B | 28.61% |
| 2009-03-31 | $5.38B | $17.98B | 29.17% |
| 2008-12-31 | $4.88B | $17.52B | 26.45% |
| 2008-09-30 | $4.55B | $19.35B | 24.55% |
| 2008-06-30 | $4.18B | $18.96B | 23.76% |
| 2008-03-31 | $3.85B | $17.98B | 23.05% |
| 2007-12-31 | $3.61B | $17.82B | 22.87% |
| 2007-09-30 | $1.93B | $15.61B | 13.00% |
| 2007-06-30 | $1.93B | $15.33B | 12.99% |
| 2007-03-31 | $1.55B | $14.32B | 10.47% |
| 2006-12-31 | $1.72B | $14.05B | 11.58% |
| 2006-09-30 | $3.17B | $15.63B | 21.24% |
| 2006-06-30 | $3.13B | $15.19B | 21.50% |
| 2006-03-31 | $3.40B | $14.44B | 23.64% |
| 2005-12-31 | $3.37B | $14.42B | 23.56% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $148.126B | $30.578B |
| Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $144.847B | 20.33 |
| Stryker (SYK) | United States | $74.230B | 24.96 |
| Boston Scientific (BSX) | United States | $55.990B | 26.43 |
| Baxter (BAX) | United States | $40.262B | 24.42 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $32.646B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $29.479B | 18.49 |
| Terumo (TRUMY) | Japan | $26.826B | 33.48 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.848B | 0.00 |
| Coloplast (CLPBY) | Denmark | $24.710B | 39.45 |
| ResMed (RMD) | United States | $20.688B | 38.16 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $18.505B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $18.021B | 0.00 |
| Insulet (PODD) | United States | $10.756B | 511.73 |
| Bio-Rad Laboratories (BIO) | United States | $10.475B | 50.28 |
| Canopy Growth (CGC) | Canada | $7.071B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.970B | 20.53 |
| Perrigo (PRGO) | Ireland | $6.683B | 12.46 |
| William Demant Holdings (WILYY) | Denmark | $6.665B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $6.420B | 0.00 |
| Haemonetics (HAE) | United States | $6.015B | 40.64 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $5.382B | 0.00 |
| GN STORE NORD (GNNDY) | Denmark | $5.276B | 27.26 |
| NuVasive (NUVA) | United States | $3.751B | 29.54 |
| Aurora Cannabis (ACB) | Canada | $3.724B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.498B | 0.00 |
| ICU Medical (ICUI) | United States | $3.474B | 22.66 |
| Neogen (NEOG) | United States | $3.331B | 55.74 |
| Hutchison China MediTech (HCM) | Hong Kong, SAR China | $2.989B | 0.00 |
| Quidel (QDEL) | United States | $2.472B | 23.46 |
| National Vision Holdings (EYE) | United States | $2.103B | 47.83 |
| Agios Pharmaceuticals (AGIO) | United States | $1.910B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.587B | 0.00 |
| InMode (INMD) | Israel | $1.452B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.251B | 28.84 |
| Aphria (APHA) | $1.250B | 0.00 | |
| AtriCure (ATRC) | United States | $1.103B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.926B | 17.34 |
| Lantheus Holdings (LNTH) | United States | $0.845B | 21.11 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.845B | 21.54 |
| NanoString Technologies (NSTG) | United States | $0.829B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.739B | 0.00 |
| Omeros (OMER) | United States | $0.677B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.660B | 37.35 |
| PetIQ (PETQ) | United States | $0.641B | 15.68 |
| Cerus (CERS) | United States | $0.574B | 0.00 |
| Quanterix (QTRX) | United States | $0.563B | 0.00 |
| HEXO (HEXO) | $0.545B | 0.00 | |
| Organigram Holdings (OGI) | Canada | $0.529B | 0.00 |
| Surmodics (SRDX) | United States | $0.527B | 55.04 |
| OraSure Technologies (OSUR) | United States | $0.511B | 30.67 |
| Owens & Minor (OMI) | United States | $0.429B | 15.88 |
| MacroGenics (MGNX) | United States | $0.389B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.381B | 27.58 |
| BioLife Solutions (BLFS) | United States | $0.340B | 104.56 |
| Meridian Bioscience (VIVO) | United States | $0.340B | 11.69 |
| Zynex (ZYXI) | United States | $0.295B | 33.33 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.274B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.261B | 0.00 |
| Bovie Medical (APYX) | United States | $0.245B | 0.00 |
| United Health Products (UEEC) | United States | $0.208B | 0.00 |
| Repro-Med Systems (KRMD) | United States | $0.183B | 0.00 |
| Vapotherm (VAPO) | United States | $0.169B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.143B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.143B | 0.00 |
| Fonar (FONR) | United States | $0.134B | 9.40 |
| Female Health (VERU) | United States | $0.129B | 0.00 |
| Liberty Health Sciences (LHSIF) | Canada | $0.128B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.122B | 0.00 |
| Chimerix (CMRX) | United States | $0.103B | 0.00 |
| United-Guardian (UG) | United States | $0.089B | 22.43 |
| Chembio Diagnostics (CEMI) | United States | $0.079B | 0.00 |
| Nephros (NEPH) | United States | $0.068B | 0.00 |
| MRI Interventions (MRIC) | United States | $0.055B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.052B | 0.00 |
| MTech Acquisition (KERN) | United States | $0.045B | 0.00 |
| Surface Oncology (SURF) | United States | $0.045B | 0.00 |
| ImmuCell (ICCC) | United States | $0.036B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.022B | 0.00 |
| Senestech (SNES) | United States | $0.019B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.019B | 0.00 |
| Myomo (MYO) | United States | $0.012B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.011B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.008B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.004B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.003B | 0.00 |
